Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals has submitted copies of its audited financial results for the fourth quarter and full financial year ended March 31, 2025, as published in Business Standard (English) and Prajasakti (Telugu) on May 21, 2025, after approval at the board meeting on May 20, 2025. For FY25, the company reported total income from operations of Rs. 4,402.08 lakhs, down from Rs. 5,087.28 lakhs in FY24, a decline of around 13.5%. Net loss for FY25 stood at Rs. 2,693.93 lakhs, wider than the Rs. 1,972.84 lakh loss reported in FY24. For Q4 FY25 alone, the company posted a net loss of Rs. 826.84 lakhs on revenue of Rs. 643.85 lakhs, compared with a loss of Rs. 584.70 lakhs on revenue of Rs. 1,218.31 lakhs in Q4 FY24. Basic and diluted EPS for FY25 came in at Rs. (12.49), and equity share capital remains at Rs. 2,156.06 lakhs.
For shareholders, this is a negative disclosure — both revenue and profitability deteriorated year-on-year, with losses deepening from Rs. 19.73 crore in FY24 to Rs. 26.94 crore in FY25. This may weigh on the stock in the near term as the company continues to report consecutive annual losses.